Reducing the heart's temperature by 2-58C is a potent cardioprotective treatment in animal models of coronary artery occlusion. The antiinfarct benefit depends upon the target temperature and the time at which cooling is instituted. Protection primarily results from cooling during the ischaemic period, whereas cooling during reperfusion or beyond offers little protection. In animal studies, protection is proportional to both the depth and duration of cooling. An optimal cooling protocol must appreciably shorten the normothermic ischaemic time to effectively salvage myocardium. Patients presenting with acute myocardial infarction could be candidates for mild hypothermia since the current door-to-balloon time is typically 90 min. But they would have to be cooled quickly shortly after their arrival. Several strategies have been proposed for ultra-fast cooling, but most like liquid ventilation and pericardial perfusion are too invasive. More feasible strategies might include cutaneous cooling, peritoneal lavage with cold solutions, and endovascular cooling with intravenous thermodes. This last option has been investigated clinically, but the results have been disappointing possibly because the devices lacked capacity to cool the patient quickly or cooling was not implemented soon enough. The mechanism of hypothermia's protection has been assumed to be energy conservation. However, whereas deep hypothermia clearly preserves ATP, mild hypothermia has only a modest effect on ATP depletion during ischaemia. Some evidence suggests that intracellular signalling pathways might be responsible for the protection. It is unknown how cooling could trigger these pathways, but, if true, then it might be possible to duplicate cooling's protection pharmacologically.
Introduction
Therapeutic whole-body hypothermia has been considered for centuries. 1 For example, the Russian approach to resuscitation of a patient in cardiac arrest in 1803 consisted of covering him with snow and then hoping for the resumption of a spontaneous circulation. 1 A century and a half later, the beneficial effect of therapeutic hypothermia during cardiac surgery was proved in canine models. 2, 3 Outside of the operating room, hypothermia has been demonstrated to protect the brain following cardiac arrest in both animal models and humans. 4, 5 The American Heart Association and the European Resuscitation Council both recommend the use of hypothermia in comatose patients resuscitated from cardiac arrest to improve the subsequent neurological recovery. 6, 7 Besides hypothermia's beneficial effect during cardiac surgery or following cardiac arrest, it has also been clearly demonstrated that even very mild hypothermia can greatly increase the heart's tolerance to myocardial ischaemia, resulting in decreases of infarct size in animal models of coronary artery occlusion. Mild hypothermia (body temperature down to 328C) has the advantage that the heart continues to pump normally and no extracorporeal support is needed. However, despite the encouraging results in animals, clinical trials of mild hypothermia in patients being revascularized for acute myocardial infarction have yielded surprisingly disappointing effects on infarct size. 8 -10 One goal of the present review is to consider why past trials have failed and propose what might be done to make cooling-induced cardioprotection more effective. We will review the literature to see whether an optimal target temperature and cooling method can be recommended. Finally, the mechanism of mild cooling's protection will be revisited. Whereas deep hypothermia stops the heart and clearly preserves ATP during ischaemia, cooling to 348C has only a modest effect on ATP depletion during ischaemia 11 but it is as protective to the rabbit heart as is ischaemic preconditioning. 12 That has caused some to suspect that the mechanism of the cardioprotective effect of mild hypothermia might be more complex than energy preservation alone. 13 
Physiological effects of mild hypothermia
Hypothermia has distinct physiological effects. Hypothermia can be classified as mild (32-358C) , moderate (28 -328C), severe (20-288C), or profound (,208C). Mild hypothermia is the only one to be used for a whole-body therapeutic purpose, as lower temperatures are increasingly life-threatening. Below 288C, the heart spontaneously fibrillates in most mammalian species. Conversely, mild whole-body hypothermia is remarkably well tolerated by both animals and humans. The physiological effects of mild hypothermia include a decrease in the heart rate and a subsequent fall in cardiac output (27% for every 18C), 3, 14 whereas stroke volume and mean arterial pressure remain unchanged. Cooling of the skin provokes an increase in systemic vascular resistance. With respect to regional haemodynamics, cerebral blood flow and intracranial pressure decrease, 3, 14 whereas renal blood flow and subsequent diuresis are increased. 15 Mild hypothermia also attenuates the cerebral metabolic rate (26 to 27% for every 18C). 16 Intestinal motility is also depressed by mild hypothermia. Blood pH changes by +0.016 unit for every 18C decrease, and serum potassium decreases as a result of its enhanced cellular uptake. 17 Hypothermia-induced hypokalaemia should be corrected with caution during hypothermia since raising serum K + usually leads to hyperkalaemia during subsequent rewarming. Other adverse effects include increased infection risk, a mild coagulopathy, 17 and hyperglycaemia caused by decreased plasma insulin levels. 18 3. The infarct-limiting property of cooling: experimental in vivo investigations
Proof of concept of the myocardial infarct-limiting property of hypothermia
Heart temperature is known to be a major determinant of infarct size in animal models of acute myocardial ischaemia. 19 -21 As an example, infarct size resulting from 30 min of regional myocardial ischaemia in in situ rabbit hearts decreases by 8% of the risk zone for every 18C decrement. 21 The infarct-limiting property of mild hypothermia has been confirmed in several species including dogs, 19 rabbits, 12,21 -25 pigs, 20,26 -28 and rats. 
What is the optimal target temperature?
Importantly, there is no threshold temperature for the cardioprotective effect of hypothermia. 19 -21 In fact, warming the heart above normothermia extends infarct size by the same degree as cooling reduces it. 21 For example, Hamamoto et al. 30 demonstrated in sheep submitted to 60 min of coronary artery occlusion that infarct size was progressively reduced when cardiac temperature during ischaemia and reperfusion was lowered by 18C decrements from 39.5 to 35.58C. As shown in Table 1 , temperature decrement during ischaemia within the mild hypothermic range has demonstrated a powerful anti-infarct effect in many studies. Figure 1 illustrates cooling to only 358C at the onset of ischaemia elicits 70% decrease in infarct size following 30 min of regional ischaemia in the open-chest rabbit. 12 Moreover, protection is still realized if the onset of cooling is delayed for 10 min. Cooling the heart to 328C at the onset of ischaemia essentially prevented infarction, and a protective effect was still evident when cooling was initiated as long as 20 min after the onset of ischaemia and, therefore, 10 min before reperfusion. 12 Furthermore, even when the ischaemic period was extended to 60 -120 min and cooling to 30-328C was initiated 20-30 min after the onset of ischaemia, the infarction process appeared to be halted when cooling was started and significant myocardial salvage was realized. 12, 22 The heart continued to beat strongly and support the rabbit's circulation.
What is the window of protection?
Cooling the heart during the ischaemic period reduces infarct size. Very early studies from the Corday Laboratory 31, 32 clearly showed that if the dog heart were retrogradely perfused with cooled arterial blood through the coronary sinus beginning 30 min after coronary occlusion and persisting for the remaining 2 1/2-3 h of the ischaemic period, infarct size was decreased by 65-90%. Figure 1 , cooling during just the last 10 min of ischaemia still afforded significant cardioprotection when the target temperature was 328C but not when it was 358C. Figure 2 merges the results of several studies investigating the effect of hypothermia to 328C initiated at different times during a 30 min period of ischaemia in rabbits, again illustrating that cardioprotection is attenuated when the onset of cooling is delayed. This raises a major logistical problem in the clinical setting since these patients with acute myocardial infarction present with ischaemia already in progress. To significantly shorten the normothermic ischaemic time cooling would have to be accomplished very soon after arrival in the hospital and efforts to effect early cooling must not come at the expense of increasing the time to reperfusion. That schedule has been difficult to implement. Cooling the body at the time of reperfusion or beyond seems to be protective in the central nervous system. 3, 33 That has led investigators to ask whether mild hypothermia might be cardioprotective when instituted only at the onset of the reperfusion phase, i.e. a postconditioning manoeuvre. Cooling to 108C at the onset of reoxygenation and glucose resupply of chick cardiomyocytes subjected to simulated ischaemia and reperfusion improved cell viability, and initiation of cooling towards the end of the simulated ischaemia further diminished cell necrosis. 34 These observations strongly suggested that cooling during the peri-reperfusion period might be successful as well. Table 2 shows the results of several intact animal studies that have investigated this possibility. 25,28,35 -39 Unfortunately, all but one 37 failed to see any effect on infarct size, and in the one positive study, cooling still included that last 5 min of a 30 min ischaemic period.
Either the much lower temperature or the non-mammalian cell type was likely responsible for the protection in the chick cardiomyocyte study. 34 Of course, cooling a patient to 108C is not feasible because that would stop the heart. However, it was found that hypothermia during reperfusion prevents microvascular damage and thereby offers some protection against the no-reflow phenomenon. 24, 35 One might, therefore, speculate that hypothermia at reperfusion protects against vascular alteration and subsequent The time of the application of the cooling strategy and not the actual time at which the target temperature was reached. In several studies, a delay was inevitable between the onset of the cooling protocol and the time of achievement of the target temperature (e.g. with low rate cooling strategy such as surface cooling). The Control value corresponds to infarct sizes observed with normothermic retroperfusion. microvascular obstruction 35 but cannot protect the cardiomyocytes.
This could mean that one should maintain cooling during the first hours of reperfusion even if cooling had been instituted early in the ischaemic period. Surprisingly, the question of whether prolonging hypothermia after reperfusion measurably adds to the anti-infarct effect has yet to be addressed. It should be noted that most patients spend 90 min in hospital prior to revascularization because of delays associated with admitting, diagnosis, and preparation for intervention. 40 Whole-body cooling during that period could produce significant reduction of the resulting infarct.
How can myocardium be cooled?
As emphasized earlier, the sooner hypothermia is achieved following the onset of ischaemia, the more cardioprotective it would be. Experimentally, some studies have been performed using topical epicardial cooling to quickly lower cardiac temperature, but this method would be difficult to implement in patients. In patients with acute myocardial infarction, the critical parameters determining benefit would be the time when cooling could be started and also the rate at which cooling could be achieved. As explained earlier, the benefit would be expected to be small or absent if the target temperature is only reached far into the reperfusion phase. Obviously, the least invasive strategy for implementing therapeutic hypothermia in patients is external cooling. This can be done using ice packs or with specific medical devices designed to promote heat exchange by a more efficient contact between the skin and the cooling medium. 2, 41, 42 Unfortunately, the cooling rate afforded by these strategies is rather low, averaging only 1-28C/h in humans. 43 That is because the cutaneous microcirculation tends to constrict when cold in an attempt to thermally insulate the body from the environment. Small laboratory animals cool faster with skin cooling than humans since their ratio of body mass to surface area is much smaller than in man. The time required to cool a rabbit weighing 2.0 -3.0 kg to 328C is still 45 min, and this does not significantly limit infarct size after 60 min of ischaemia. 44 Although it is unlikely that patients with acute myocardial infarction would experience any anti-infarct benefit from conventional external cooling, this strategy is reported to be beneficial following cardiac arrest when even delayed hypothermia improves overall survival and neurological recovery after resuscitation.
2,41,42
Other strategies have been proposed to induce therapeutic hypothermia. Some examples include endovascular cooling with intravenous thermodes, infusion of cold intravenous fluids, gastric lavage Cooling the ischaemic myocardium with cold fluid through a nasogastric catheter, and even urinary bladder lavage. 42 Most of those techniques have been investigated in the clinics for their neuroprotective abilities. 42 The one that has been investigated for a cardioprotective therapy is endovascular cooling. 26, 45, 46 In human-sized pigs, this strategy afforded promising results when cooling was initiated early during ischaemia. 26, 45 A clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) clearly demonstrated the feasibility of that strategy, 46 but disappointingly did not show a significant cardioprotective benefit, 8 probably because of an insufficient cooling rate that resulted in normothermia during most of the ischaemic period. 47 
Ultra-fast cooling
Accordingly, other strategies have been proposed that elicit a much faster rate of cooling which should increase the degree of cardioprotection in the clinical setting. Examples include extracorporeal blood cooling 12 or total liquid ventilation with temperature-controlled perfluorocarbons. 25, 48 These techniques can decrease cardiac temperature to 328C within 3 -5 min in rabbits. A pericardial perfusion circuit has also been proposed. 49 Unfortunately, all these strategies would be challenging to implement in patients presenting with myocardial infarction since they are very invasive and would significantly delay reperfusion by angioplasty or thrombus extraction. A promising technique could be peritoneal lavage, which, although still invasive, should be easier to institute than any of the above-mentioned methods. As seen in patients with malignant hyperthermia, it can cool a patient very quickly. 50 Whether any of these ultra-fast cooling strategies would be beneficial in humans with STEMI remains to be investigated.
Mechanism of cooling-induced cardioprotection
The mechanism of hypothermia-induced cardioprotection has mostly been investigated in experimental models receiving cold cardioplegia. The temperature of the heart is reduced to very low levels, which, among other things, arrests it. 13, 51 However, mechanisms are likely to be quite different for mild hypothermia of an in vivo beating heart and an arrested heart exposed to cold cardioplegia. In beating hearts, one could, for example, argue that the cardioprotection might be related to the bradycardia elicited during ischaemia. However, this is unlikely because the relationship between infarct size and temperature was unchanged when normothermic heart rate was restored by pacing in hypothermic rabbits. 21, 52 It is therefore commonly assumed that hypothermia protects the heart, at least in part, through reduced cardiac metabolism. This assumption has been amply supported by studies performed during cold cardioplegia (,208C The time of the application of the cooling strategy and not the actual time at which the target temperature was reached. In several studies, a delay was inevitable between the onset of the cooling protocol and the time of achievement of the target temperature (e.g. with low rate cooling strategy such as surface cooling).
decreased demand for ATP by reduced Na + /K + -ATPase activity. 65 An NMR study in isolated newborn rabbit hearts further confirmed that deep cooling (128C) with cold crystalloid cardioplegia limited acidosis and calcium and sodium cellular overload during ischaemia/reperfusion. 13 Deep hypothermia (178C) also limited mitochondrial calcium overload in Langendorff guinea pig hearts undergoing ischaemia. 66 Although deep hypothermia tends to increase baseline reactive oxygen species formation during normoxia, it limits the burst following ischaemia-reperfusion. 66 Using electron spin resonance spectroscopy in isolated reperfused rat heart, investigators have observed reduced free-radical generation at reperfusion following ischaemia at 48C. 67 Deep hypothermia reduces several modulators of the mitochondrial permeability transition pore (mPTP), i.e. ATP depletion, calcium overload, and generation of reactive oxygen species. Mild hypothermia (328C) inhibited calcium-induced mPTP opening in ventricular samples from rabbit hearts subjected to ischaemia alone or to ischaemia followed by 10 min of reperfusion. 48 Suppression of mPTP formation at reperfusion is thought to be the mode of action of ischaemic preconditioning 68 and ischaemic postconditioning. 69 Thus it is reasonable to speculate that hypothermia acts, at least in part, through the inhibition of MPTP formation. However, the manner of modulation of mPTP opening is probably different from that afforded by pre-and postconditioning since the latter strategies are believed to trigger signal transduction pathways that determine the fate of the previously ischaemic myocardium during the first minutes of reperfusion, 69 -73 whereas hypothermia seems to exert its protection during ischaemia. 48 Opening of mPTP at reperfusion only occurs if the heart has been injured by a period of prolonged ischaemia. The nature of that injury is poorly understood, but Honda et al. 74 referred to it as 'priming'. Mild hypothermia may act to lessen that ischaemic injury. The protection from mild hypothermia is proportional to the decrease in temperature which argues against any off/on type of mechanism. A direct effect of mild hypothermia on enzyme kinetics seems unlikely to be the protective mechanism since most enzymes are not so temperature-dependent. Hearts function quite well over the entire range of mild hypothermia (32-388C). An intriguing possibility is that mild hypothermia might somehow activate cardioprotective signal transduction pathways. Ning et al. 75 demonstrated that cold cardioplegia (308C) preserves mitochondrial protein gene expression during hypoxia, including genes coding for HSP70, ANT 1 , and b-F 1 -ATPase. 76 They observed that neither ATP levels nor anaerobic metabolism is linked to mRNA expression of these latter proteins. 77 Ning et al. 77 also showed that moderate hypothermia (308C) promotes expression of proteins involved in cell survival, although it inhibits induction of p53 protein. It is, therefore, reasonable to hypothesize that mild hypothermia triggers its protection through thermal sensors. This hypothesis is supported by studies from Halestrap's group, which reported that a short period of perfusion at 268C in isolated rat hearts induced a preconditioning-like protection which increased protein kinase C-1 translocation to the particulate fraction (an index of its activation) and phosphorylated AMP-activated protein kinase. 78 In one recent study in chick cardiomyocytes undergoing simulated ischaemia, cooling to 258C just before reoxygenation protected the cells. 34 More importantly that protection could be blocked by either a PKC or a nitric oxide synthase (NOS) blocker indicating signal transduction. Protection in the latter study, however, seemed to mimic that of postconditioning rather than that of mild hypothermia since the critical time for cooling was during reoxygenation rather than simulated ischaemia, and PKC and NOS are well-known components of the signal transduction pathways of pre-and postconditioning. Also cooling was much more severe. All chemical reactions are at some point temperature-dependent, but the temperature coefficients (Q 10 ) for the various mammalian enzymes vary widely. The possibility that one particular enzyme might be very sensitive to temperature and could serve as a sensor to implement the cardioprotective effect of mild hypothermia through cell signalling is an attractive hypothesis, but, of course, that enzyme could be very difficult to find. Hypothermia seems to protect against injury during ischaemia, whereas ischaemic preconditioning protects against injury during reperfusion. Because of the different mechanisms, it is possible to add the two together to produce additive protection. 12 It is currently possible to pharmacologically postcondition a heart 79, 80 and such an intervention is thought to protect by a mechanism identical to that of preconditioning. Thus, it should be possible to combine mild hypothermia during ischaemia with a postconditioning agent at reperfusion. The primary impediment to using mild hypothermia clinically has been the logistics of implementing it quickly after the onset of ischaemia. However, if signalling pathways turn out to be responsible for the protection of mild hypothermia, then pharmacological activation of those pathways would likely be simpler to implement and such an agent could possibly even be given by EMS personnel.
Cooling and cardioprotection: STEMI clinical data
Soon after the turn of the twenty-first century, the promising experimental results regarding the cardioprotective effect of cooling inspired several clinical trials testing the feasibility of mild hypothermia and safety in STEMI patients. 46, 81, 82 As shown in Table 3 large-scale clinical trials (COOL-MI 8 and ICE-IT 10 ) were conducted using endovascular cooling. Both studies assessed infarct size using single-photon emission computed tomography (SPECT). The results of these studies have not yet been published in peer-reviewed journals, but they have been summarized in several reviews. 41, 83, 84 In the COOL-MI study (COOLing as an adjunctive therapy to percutaneous intervention in patients with acute Myocardial Infarction), 392 STEMI patients were enrolled within 6 h following the onset of symptoms. 8 Patients were assigned to either treatment with a percutaneous coronary intervention alone or to cooling with an endovascular cooling device (Reprieve Temperature Therapy System, Radiant Medical, Redwood City, CA, USA) prior to revascularization. The percutaneous coronary intervention was accomplished a mean of 18 min after cooling was instituted, with a mean temperature of 35.08C at the moment of reperfusion. As shown in Table 3 , cooling did not provide an overall significant reduction in infarct size, except in a subgroup of patients with anterior myocardial infarction who were cooled to ,358C at the time of revascularization. 8 The overall negative result of that study might have been biased since the average door-to-balloon time in cooled patients was 18 min longer than in control patients (110 vs. 92 min).
In the ICE-IT study (Intravascular Cooling Adjunctive to Primary Coronary Intervention), the design was similar to COOL-MI with the inclusion of 228 patients randomized to either normothermic revascularization or to revascularization with mild hypothermia using another endovascular device (Innercool by Celsius Control System, San Diego, CA, USA). 10 Hypothermia again did not provide a significant benefit regarding infarct size in the whole population ( Table 3) . A trend for a benefit was observed in the subgroup with anterior infarction with a body temperature of ,358C at the time of reperfusion. Interestingly, a subanalysis of the six sites with the best protocol compliance out of the 22 participating sites also demonstrated a significant reduction in infarct size with cooling compared with conventional revascularization (244%). These data suggest, as emphasized above, that the overall negative result of the COOL-MI and ICE-IT trials was related to a delay in the institution of hypothermia and/or to an insufficient cooling rate which resulted in little shortening of the normothermic ischaemic period. A further study (COOL-MI II) was accordingly recently conducted with an earlier, deeper, and faster cooling protocol, with cooling started in the emergency room rather than in the catheterization laboratory. The results of this last trial are not yet available. It has conversely been suggested that hyperthermia may worsen the clinical outcome in patients with myocardial infarction. 85 In experimental conditions, Chien et al. 21 found not only that hypothermia could diminish infarct size but also that hyperthermia could increase it. One would, therefore, speculate that therapeutic hypothermia would also be indicated to reverse the adverse effects of hyperthermia. A general relationship between clinical outcome and body temperature may well exist.
Cardiac resuscitation
Another setting in which the protective effect of cooling would be relevant is cardiopulmonary resuscitation. Cooling after the heart is restarted can indeed protect the central nervous system, as has been previously shown, 5 but it may also protect the heart since myocardial ischaemia is a common cause of cardiac arrest. 41, 84 Theoretically, the cardiac benefit would even be greater for those patients than for 'typical' STEMI as the time before revascularization is prolonged by the resuscitation time. There is controversy as to whether resuscitated patients should be immediately submitted to a coronary intervention 41, 84 since the use of hypothermia is basically recommended for comatose survivors after out-of-hospital cardiac arrest with ventricular fibrillation. 6, 7 Importantly, the combination of cooling and percutaneous intervention is at least feasible and should be safe in those patients. 41, 84 6. Conclusion
In conclusion, cooling the myocardium with whole-body mild hypothermia is a very potent cardioprotective manoeuvre, at least in the experimental setting. The benefit depends upon the rapidity with which cooling is instituted and by how much it shortens the normothermic ischaemic time. To afford a clinical benefit, a cooling strategy should accordingly be designed to achieve the target temperature well before the time of revascularization. The depth of cooling is also important. Temperatures in the range of 32-358C are considered safe. Yet these temperatures exert a powerful anti-infarct effect in animal studies. Finally, more studies of mild hypothermia are needed to determine its actual mechanism, compared with deep hypothermia that acts through energy preservation.
